Other Trials and Emerging Data in EGFR-Mutant NSCLC Treatment: Anticipating the Future Treatment Landscape

August 23, 2024

By Martin Dietrich, MD, PhD
Wade Iams, MD

Opinion

Video

Medical oncologists discuss the overall research landscape in advanced EGFR-mutant NSCLC, highlighting exciting trials and emerging data in the evolving treatment space.

EP: 1.Assessing FLAURA2's Influence: How Has It Shaped Your First-Line Treatment Strategy?

EP: 2.Evaluating MARIPOSA’s Secondary Analysis in High-Risk Advanced EGFR-Mutant NSCLC: Practical Implications

EP: 3.Expert Insights from PALOMA-3: Highlights from ASCO 2024

EP: 4.Subcutaneous Amivantimab: Overcoming Treatment Barriers and Shaping Advanced NSCLC Strategies

EP: 5.Implementing Proactive Management Strategies with Amivantamab in Clinical Practice: Expert Insights

EP: 6.Insights from TROPION-Lung05 and HERTHENA-Lung01: Perspectives on the Future Role of ADCs in Advanced EGFR-Mutant NSCLC

Now Viewing

EP: 7.Other Trials and Emerging Data in EGFR-Mutant NSCLC Treatment: Anticipating the Future Treatment Landscape

Video content above is prompted by the following:

What other trials/emerging data are you excited about in this treatment space? How do you anticipate the future treatment landscape to evolve for EGFR-mutant NSCLC?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!